BioSpace News Archive

The patent belongs to BiondVax’s portfolio family titled “Multimeric Multi-Epitope Influenza Vaccines” and has now been granted in over 30 countries.

The purpose of the Agreement is to develop and commercialize the Antigen Express AE37 immunotherapeutic vaccine for prostate cancer in the People’s Republic of China (including Taiwan, Hong Kong, and Macau).

This removes the requirement for pediatric clinical studies to support tucatinib market authorization application for treatment of metastatic breast cancer in Europe.

NRGene, the worldwide leader in genomic assembly and analysis, has partnered with leading researchers to make a significant impact on global agricultural research.

SVP-Rapamycin is Selecta’s proprietary, clinical-stage anti-drug antibody (ADA) prevention and immune tolerance technology.

Biometric Remote Monitoring Company Actively Prepares for Product Launch by Hiring Sales and Expanding Business Development Initiatives

This prospective, 40-site, 250-patient trial will evaluate long-term fusion and pain reduction in patients receiving SImmetry Sacroiliac Joint Fusion.

He is replacing Jacques Attali for the remainder of the term, until the Annual Shareholder’s meeting is called to approve the 2018 financial statements.

This novel Sorrento CAR-T technology has already been utilized preclinically to generate CD38 CAR-T and CD19 CAR-T cells.

As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.